Cipher Pharmaceuticals Inc.

CPH

CA17253X1050

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 21:00:00 14/06/2024 BST			5-day change	1st Jan Change
8.54 ^CAD	+0.47%		-4.04%	+54.15%

05-13	Cipher Pharmaceuticals Downgraded to Hold at Stifel GMP Following Share-Price Gains; Price Target Raised to C$9.50	MT
05-10	Transcript : Cipher Pharmaceuticals Inc., Q1 2024 Earnings Call, May 10, 2024

Cipher Pharmaceuticals Inc. Elects Laurence Terrisse-Rulleau as Director

May 11, 2018 at 05:00 pm

Cipher Pharmaceuticals Inc. elected Dr. Laurence Terrisse-Rulleau as Director of the company at the Annual and Special Meeting of Shareholders held on May 10, 2018.

Latest news about Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Downgraded to Hold at Stifel GMP Following Share-Price Gains; Price Target Raised to C$9.50	05-13	MT
Transcript : Cipher Pharmaceuticals Inc., Q1 2024 Earnings Call, May 10, 2024	05-10
Cipher Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024	03-15
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023.	03-14	CI
Cipher Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Cipher Pharmaceuticals Q4 Profit Falls 61% on Charges	03-14	MT
Cipher Pharmaceuticals Brief: Q4 Net income and earnings per common share were US$7.7 million and $0.32, respectively	03-14	MT
Cipher Pharmaceuticals Brief: Q4 Total revenue was US$4.9 million, consistent with Q4 2022	03-14	MT
Cipher Pharmaceuticals Upgraded to Buy at Stifel GMP; Price Target Raised to C$8.00	02-14	MT
Cipher Pharmaceuticals Brief: Announcing that its common shares are now trading on the OTCQX Best Market	01-29	MT
Cipher Pharmaceuticals Announced Normal Course Issuer Bid	11-15	MT
Cipher Pharmaceuticals Brief: Announcing Normal Course Issuer Bid	11-15	MT
Cipher Pharmaceuticals Inc. announces an Equity Buyback for 1,337,195 shares, representing 5.57% of its issued share capital.	11-15	CI
Cipher Pharmaceuticals Inc. authorizes a Buyback Plan.	11-14	CI
Cipher Pharmaceuticals Seeks Acquisitions	11-10	CI
Transcript : Cipher Pharmaceuticals Inc., Q3 2023 Earnings Call, Nov 10, 2023	11-10
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on September 19, 2022.	11-09	CI
Cipher Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Cipher Pharmaceuticals Announced Final Results of Substantial Issuer Bid	12/10/23	MT
Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on September 5, 2023.	12/10/23	CI
Cipher Pharmaceuticals Inc.'s Equity Buyback announced on September 5, 2023, has closed with 1,290,321 shares, representing 5.1% for CAD 6 million.	10/10/23	CI
Cipher Pharmaceuticals Inc.'s Equity Buyback announced on September 19, 2022, has expired with 284,843 shares, representing 1.13% for CAD 1.03 million.	20/09/23	CI
Cipher Pharmaceuticals Plans Substantial Issuer Bid	05/09/23	MT
Cipher Pharmaceuticals Inc. announces an Equity Buyback for CAD 6 million worth of its shares.	05/09/23	CI

Chart Cipher Pharmaceuticals Inc.

Duration

Period

More charts

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cipher Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.54 CAD

Average target price

10.67 CAD

Spread / Average Target

+24.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CIPHER PHARMACEUTICALS INC.	+54.15%	150M
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals